UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 5, 2018
WAVE LIFE SCIENCES LTD.
(Exact name of registrant as specified in its charter)
| Singapore | 001-37627 | Not Applicable | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 7 Straits View #12-00 Marina One East Tower Singapore 018936 |
018936 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: +65 6236 3388
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 7.01 Regulation FD Disclosure.
From time to time, Wave Life Sciences Ltd. (the “Company”), presents and/or distributes slides and presentations to the investment community at various industry and other conferences to provide updates and summaries of its business. On January 5, 2018, the Company updated its corporate presentation, which is available on the Investors & Media section of the Company’s website at http://ir.wavelifesciences.com/. This presentation is attached as Exhibit 99.1 and is incorporated by reference herein.
The information in Item 7.01 of this Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
Description | |
| 99.1 | Corporate presentation of Wave Life Sciences Ltd., dated as of January 5, 2018 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| WAVE LIFE SCIENCES LTD. | ||||
| Date: January 5, 2018 | /s/ Keith C. Regnante | |||
| Keith C. Regnante Chief Financial Officer | ||||
Exhibit 99.1
Wave Life Sciences Corporate Presentation January 5, 2018
Forward looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, collaborations and partnerships, regulatory activities and timing thereof, competitive position, potential growth opportunities, use of proceeds and the effects of competition are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause the actual results, performance or achievements of Wave Life Sciences Ltd. (the “Company”) to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect the Company’s business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, including those listed under Risk Factors in the Company’s Form 10-K and other filings with the SEC, some of which cannot be predicted or quantified and some of which are beyond the Company’s control. The events and circumstances reflected in the Company’s forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that the Company may face. Except as required by applicable law, the Company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. 2
Genetic medicines company Developing targeted therapies for patients impacted by rare diseases Rationally designed stereopure nucleic acid therapeutics Utilizing multiple modalities including antisense, exon skipping and RNAi 6 proprietary neurology development programs by the end of 2018 Expertise and core focus in neurology 2 Phase 1b/2a trials initiated in Huntington’s disease DMD Exon 51 trial initiated Clinical data readouts anticipated in 2019 for first 3 programs Robust R&D platform, ability to partner additional therapeutic areas Cash position $169MM as of September 30 2017 3
Paving the way to potentially safer, more effective medicines 1 6 3 10K+ first to design neurology clinical studies Wave stereopure and bring stereopure development initiated oligonucleotides and allele-specific programs in 2017 created and medicines to clinic by end of 2018 analyzed to date 5 12+ 5 25M+ nucleic acid discovery programs therapeutic total potentially modalities being areas under addressable patients advanced with Wave active investigation amenable to Wave’s stereopure chemistry partnered and proprietary programs 4
Pipeline spanning multiple modalities, novel targets ESTIMATED U.S. ADDRESSABLE NEXT ANTICIPATED DISEASE TARGET BIOMARKER PATIENTS * MILESTONES CNS Huntington’s disease mHTT SNP1 mHTT ~10k / ~35k A Phase 1b/2a Top line data 1H 2019 Huntington’s disease mHTT SNP2 mHTT ~10k / ~35k A Phase 1b/2a Top line data 1H 2019 Amyotrophic lateral sclerosis C9orf72 dipeptide ~1,800 A Trial initiation Q4 2018 Frontotemporal dementia C9orf72 dipeptide ~7,000 A Trial initiation Q4 2018 MUSCLE Duchenne muscular dystrophy 51 exon 51 dystrophin ~2,000 E Phase 1 Top line data Q3 2018 Duchenne muscular dystrophy 53 exon 53 dystrophin ~1,250 E Trial initiation Q1 2019 HEPATIC APOC3 A undisclosed A undisclosed A A = allele-specific silencing. E = exon skipping. *Estimates of U.S. prevalence and addressable population by target based on publicly available data and are approximate. *For Huntington’s disease, numbers approximate manifest and pre-manifest populations, respectively 5
Neurology leadership Current programs Huntington’s disease (HTT SNP1) Huntington’s disease (HTT SNP2) Duchenne muscular dystrophy (exon 51) Duchenne muscular dystrophy (exon 53) Amyotrophic lateral sclerosis (C9orf72) Frontotemporal dementia (C9orf72) Discovery engine Neuromuscular diseases DMD (additional exons) Spinal muscular atrophy (SMN2) Charcot-Marie-Tooth type 1A (PMP22) Neurodegenerative movement disorders Spinocerebellar ataxia (ATXN3) Opportunities for expansion Neurodegenerative movement disorders Parkinson’s disease Progressive supranuclear palsy Neurodegenerative dementias Alzheimer’s disease Developmental diseases Fragile X Batten disease Neurophysiology/ neuropsychiatry/pain Epilepsy Schizophrenia 6
Broad platform relevance across therapeutic areas CNS Muscle 7
Building the optimal, stereopure medicine STANDARD OLIGONUCLEOTIDE APPROACHES Pharmacologic properties include >500,000 permutations in every dose Impact: Unreliable therapeutic effects Unintended off-target effects WAVE RATIONAL DESIGN Stereochemistry enables precise control, ability to optimize critical constructs into one defined and consistent profile Impact: Potential for safer, more effective, targeted medicines that can address difficult-to-treat diseases 8
Creating a new class of oligonucleotides WAVE RATIONAL DESIGN Source: Iwamoto N, et al. Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nature Biotechnology. 2017. 9
Chemistry may optimize medicines across multiple dimensions Improved Stability Stability of stereopure molecules with reduced PS content (liver homogenate) Controlled Immunogenicity Human TLR9 activation assay with 5mC modified CpG containing MOE gapmer Enhanced Delivery Stereochemistry enables enhanced delivery of oligonucleotides Oligonucleotides exposure (spinal cord) Cytokine induction in human PBMC assay IL-6 MIP-1β Uptake without transfection agent between a stereopure and stereorandom oligonucleotide Gymnotic uptake of ASOs:18h differentiating myoblasts Data represented in this slide from in vitro studies. Experimental conditions: Human TLR9 assay – Source: Ohto U, et al. Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9, Nature 520, 702-705, 2015. Intracellular trafficking assay – Cells were washed and fixed and oligos were detected by viewRNA assay and visualized on 10 immunofluorescence microscope with deconvolution capabilities. Z-stacks were taken to eliminate artifacts.
Stereochemistry is applicable across modalities Antisense RNAi Exon skipping * Stereochemistry allows for novel approaches to previously difficult diseases and inaccessible targets 11
Transforming nucleic acid therapeutics SUPERIOR PHARMACOLOGY + SCALABLE SYNTHESIS MULTIMODALITY Antisense RNAi Splice Correction Exon skipping Gene editing BROAD IMPACT CNS Muscle Eye Liver Skin UNLOCKING THE PLATFORM Broad addressable patient population across multiple therapeutic areas 12
Neurology CNS Muscle 13
Huntington’s Disease 14
Neuro HD Huntington’s Disease: a hereditary, fatal disorder Autosomal dominant disease, characterized by cognitive decline, psychiatric illness and chorea; fatal No approved disease-modifying therapies Expanded CAG triplet repeat in HTT gene results in production of mutant huntingtin protein (mHTT); accumulation of mHTT causes progressive loss of neurons in the brain Wildtype (healthy) HTT protein critical for neuronal function; suppression may have detrimental long-term consequences 30,000 people with Huntington’s disease in the US; another 200,000 at risk of developing the condition DNA CAG Repeat RNA RNA wildtype (healthy) allele mutant allele Normal CAG Repeat Expanded CAG Repeat Healthy protein (HTT) Mutant protein (mHTT) Sources: Auerbach W, et al. Hum Mol Genet. 2001;10:2515-2523. Dragatsis I, et al. Nat Genet. 2000;26:300-306. Leavitt BR, et al. J Neurochem. 2006;96:1121-1129. Nasir J, et al. Cell. 1995;81:811-823. Reiner A, et al. J Neurosci. 2001;21:7608-7619. White JK, et al. Nat Genet. 1997;17:404-410. Zeitlin S, et al. Nat Genet. 1995;11:155-163. Carroll JB, et al. Mol Ther. 2011;19:2178-2185. 15
Wave approach: novel, allele-specific silencing Neuro HD Utilize association between single nucleotide polymorphisms (SNPs) and genetic mutations to specifically target errors in genetic disorders, including HD. Allele-specificity possible by targeting SNPs associated with expanded long CAG repeat in mHTT gene Approach aims to lower mHTT transcript while leaving healthy HTT relatively intact Potential to provide treatment for up to 70% of HD population (either oligo alone could address approximately 50% of HD population) expanded SNP 1 ~50% of patients SNP 2 ~50% of patients ~20% of patients may carry both SNP1 AND SNP 2 Total: Due to overlap, an estimated ~70% of the total HD patient population carry SNP 1 and/or SNP 2 Source: Kaye, et al. Personalized gene silencing therapeutics for Huntington disease. Clin Genet 2014: 86: 29–36 16
Two simultaneous Phase 1b/2a clinical trials Neuro HD Two parallel global placebo-controlled multi-ascending-dose trials for WVE-120101, WVE-120102 Primary objective: assess safety and tolerability of intrathecal doses in early manifest HD patients Additional objectives: exploratory pharmacokinetic, pharmacodynamic, clinical and MRI endpoints Blood test to determine presence of SNP 1 or SNP 2 done at pre-screening Approximately 50 patients per trial Key inclusion criteria: age ³25 to £65, stage I or II HD Top line data anticipated 1H 2019 17
Neuro HD Mutant huntingtin: a powerful, novel biomarker Novel immunoassay allows for quantification of mutant huntingtin, the cause of HD Level of mHTT detected is associated with time to onset, increased with disease progression, and predicts diminished cognitive and motor dysfunction Assay currently being utilized in clinical studies Novel approach enables precise measurement of target engagement and effect Source: Wild E, et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patients. J. Clin. Invest. 2015:125:1979–1986. Edward Wild, MA MB BChir PhD MRCP Principal Investigator at UCL Institute of Neurology and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, London 18
Neuro HD Selective reduction of mHTT mRNA & protein Reporter Cell Line* 19
Neuro HD Demonstrated delivery to brain tissue WVE-120101 and WVE-120102 distribution in cynomolgus non-human primate brain following intrathecal bolus injection CIC = cingulate cortex In Situ Hybridization ViewRNA stained tissue Red dots are WVE-120101 oligonucleotide. Arrow points to nuclear and perinuclear distribution of WVE- 120101 in cingulate cortex CIC = cingulate cortex. CN = caudate nucleus. CN = caudate nucleus In Situ Hybridization ViewRNA stained tissue Red dots are WVE-120102 oligonucleotide. Arrow points to nuclear and perinuclear distribution of WVE-120102 in caudate nucleus 20
Duchenne Muscular Dystrophy (DMD) 21
Neuro DMD DMD: a progressive, fatal childhood disorder Fatal, X-linked genetic neuromuscular disorder characterized by progressive, irreversible loss of muscle function, including heart and lung Genetic mutation in dystrophin gene prevents the production of dystrophin protein, a critical component of healthy muscle function Symptom onset in early childhood; one of the most serious genetic diseases in children worldwide Current disease modifying treatments have demonstrated minimal dystrophin expression and clinical benefit has not been established Impacts 1 in every 3,500 newborn boys each year; 20,000 new cases annually worldwide 22
Neuro DMD Wave approach: meaningful restoration of dystrophin production through exon skipping Meaningful restoration of dystrophin production is expected to result in therapeutic benefit Exon-skipping antisense approaches may enable production of functional dystrophin protein Initial patient populations are those amenable to Exon 51 and Exon 53 skipping 23
Neuro DMD Exon 51: WVE-210201 clinical program WVE-210201 Phase 1 clinical trial initiated November 2017 – Design: Multicenter, double-blind, placebo-controlled, single ascending dose study with I.V. administration – Primary endpoint: Safety and tolerability – Inclusion criteria: ages 5 to 18, amenable to exon 51 skipping Ambulatory and non-ambulatory boys eligible, including those previously treated with eteplirsen (following appropriate washout period) – Readout expected Q3 2018 – Planned open-label extension (OLE) with muscle biopsy and ³2-years of follow-up WVE-210201 planned efficacy study – Design: Double-blind, placebo-controlled, multi-dose study assessing dystrophin expression and clinical outcomes – Measurement of dystrophin via standardized Western Blot – Interim analysis of dystrophin expression in muscle biopsies – Efficacy readout anticipated 2H 2019 Exploring intravenous and subcutaneous formulations for WVE-210201 24
Neuro DMD Exon 51: improved skipping efficiency RNA skipping determined by quantitative RT-PCR Wave isomers demonstrated a dose-dependent increase in skipping efficiency Free uptake at 10uM concentration of each compound with no transfection agent Same foundational stereopure chemistry for Wave isomers; individually optimized to assess ideal profile 25
Neuro DMD Exon 51: increased dystrophin restoration dystrophin (400-427 kDa) vinculin (120 kDa) *Analogs WVE-210201 dystrophin (400-427 kDa) vinculin (120 kDa) Dystrophin protein restoration in vitro was quantified to be between 50-100% of normal skeletal muscle tissue lysates, as compared to about 1% by drisapersen and eteplirsen analogs Experimental conditions: DMD protein restoration by Western Blot in patient-derived myotubes with clear dose effect. Free uptake at 10uM concentration of each compound with no transfection agent 26
Neuro DMD Exon 51: target engagement in healthy non-human primate Nested PCR Assay 5 doses @ 30 mg/kg /week for 4 weeks healthy NHP by subcutaneous dosing Experimental conditions: Muscle tissues were collected 2 days after the last dose and fresh frozen. Total RNAs were extracted with phenol/chloroform and converted to cDNA using high capacity kit. Nested PCR assay was performed and analyzed by fragment analyzer. 27
Neuro DMD Exon 51: no apparent tissue accumulation observed Single in-vivo I.V. dose at 30 mpk in MDX 23 mice Standard oligonucleotides tend to accumulate in liver and kidney Wave rationally designed oligonucleotides optimized to allow compound to clear more effectively WVE-210201 demonstrated wide tissue distribution in dose dependent fashion No apparent accumulation observed after multiple doses Experimental description: Oligo quantifications in tissues were performed using hybridization ELISA assay 28
Neuro DMD Exon 53: Stereopure lead molecules advancing toward candidate RNA skipping determined by quantitative RT-PCR Free uptake at 10uM and 3uM concentration of each compound with no transfection agent Current published clinical dystrophin levels achieved for Exon 53 are ~1% Early Exon 53 data suggests initial skipping efficiency around 20% pre-optimization 29
C9orf72 Amyotrophic Lateral Sclerosis (ALS) Frontotemporal Dementia (FTD) 30
Neuro C9orf72 C9orf72: a critical genetic risk factor C9orf72 gene provides instructions for making protein found in various tissues, with abundance in nerve cells in the cerebral cortex and motor neurons C9orf72 genetic mutations are the strongest genetic risk factor found to date for the more common, non-inherited (sporadic) forms of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD); GGGGCC repeat drives the formation and accumulation of dipeptide repeat proteins that accumulate in brain tissue First pathogenic mechanism identified to be a genetic link between familial (inherited) ALS and FTD Most common mutation identified associated with familial ALS and FTD Availability of dipeptide biomarker in CSF has potential to accelerate drug development expanded GGGGCC repeat de ript 31
Neuro C9orf72 Amyotrophic lateral sclerosis Neurodegenerative disease characterized by the progressive ~40% degeneration of motor neurons in the brain and spinal cord Affects approximately 15,000-20,000 people in the US with a median ~10% survival of 3 years C9orf72 is present in approximately 40% of familial ALS and 8-10% of sporadic ALS; currently the most common demonstrated mutation related to ALS, far more so than SOD1 or TDP-43 Pathogenic transcripts of the C9orf72 gene contain hundreds to ~8-10% thousands of hexanucleotide repeats compared to 2-23 in wild-type transcripts; dominant trait with high penetrance ~90% Initiation of clinical study expected 4Q ‘18 Source: State of play in amyotrophic lateral sclerosis genetics Alan E Renton, Adriano Chiò & Bryan J. Traynor Nature Neuroscience 17, 17–23 (2014) doi:10.1038/nn.3584 32
Neuro C9orf72 Frontotemporal dementia Progressive neuronal atrophy with loss in the frontal and temporal cortices characterized by personality and behavioral changes, as well as gradual ~38% impairment of language skills 10%—50% Affects approximately 55,000 people in the US Second most common form of early-onset dementia after Alzheimer’s disease in people under the age of 65 Up to 50% of FTD patients have a family history of dementia, many inheriting FTD as an autosomal dominant trait with high penetrance ~6% Pathogenic transcripts of the C9orf72 gene contain hundreds to thousands of hexanucleotide repeats compared to 2-23 in wild-type transcripts 50%—90% Initiation of clinical study expected 4Q ‘18 Sources: Familial aggregation in frontotemporal dementia, M. Stevens, MD; C.M. et al, Neurology 1998. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Elisa Majounie et al Lancet Neurology March 9, 2012 DOI:10.1016/S1474-4422(12)70043-1 33
Selective silencing in vivo of expanded Neuro C9orf72 C9orf72 repeat transcripts Wave has developed a series of highly optimized antisense compounds which selectively silence the repeat containing transcript in C9orf72 transgenic mice These compounds show target engagement across cell types and regions of the nervous system critically implicated in ALS WVE-3972-01 WVE-3972-01 Experimental description: Samples were analyzed using quantitative PCR (Taqman assay) 34
Neuro C9orf72 Durable reduction of dipeptides and RNA foci in vivo Wave’s candidate (WVE-3972-01) demonstrates durable reduction of dipeptides and reductions in RNA foci Data is consistent across blinded studies in independent laboratories (collaboration with Professor Bob Brown, U. Mass) Durable reduction of dipeptide in vivo Reductions in RNA foci in vivo (8 weeks) Spinal Cord Cortex lei 1 5 0 2-weeks 4-weeks 8-weeks 1 5 0 2-weeks 4-weeks 8-weeks u c 1 .5 n PBS) means+SEM) 100 1 0 0 1 0 0 r to 1 ..0 e p d ze foci al i 5 0 5 0 f m 0 .5 PolyGP expression, o or (n 0 0 0 .0 (Relative S t e S t e S t e S Nu mber PBS Control Candidate B a B a B a t e S t e S t e a B a B a P di d P di d P di d P B i d P i d P i d n n n d d d a a a n n n a a a C C C C C C CONFIDENTIAL 35
Emerging areas 36
Liver Pfizer hepatic collaboration Initiated May 2016 40 Exploring targets across modalities, including ASO and ssRNAi $M upfront Up to 5 hepatic-metabolic programs payment 3 targets declared; APOC3, 2 undisclosed Option to declare 2 additional targets Access to Pfizer’s hepatic targeting technology Potentially increasing potency beyond GalNAc 871 Freedom to leverage beyond collaboration targets $M in potential milestone payments and royalties 37
Liver Stereopure ASOs: improved in vivo potency, extended duration Potency equivalent to state-of-the-art GalNAc conjugated double strand RNAi (ED50 0.3 mg/kg) Demonstrated increase in durability over GalNAc conjugated stereorandom ~7 fold ED50 ~2.0 mg/kg ED50 0.3 mg//kg Dosing Days 1,3 at 5mpk Experimental description: Male human APOC3 transgenic mice were dosed with APOC3 ASOs with indicated doses. APOC3 mRNA quantification in the liver was performed using Taqman assay specific for hAPOC3. For protein analysis, plasma samples were collected weekly and analyzed by ELISA assay specific to human APOC3 protein. 38
% m R N A R e m a in in g ( m M A L A T 1 / m H P R T 1 ) 1 1 1 2 5 7 0 2 5 0 5 0 5 0 5 0 Back P B S of ( — Control ) the 5 0 m g Stereopure Experimental SR 5 0 m g 1 eye 10X 5 m g week Single description: lower Stereopure 5 0 m g ASOs: % m R N A R e m a in in g intravitreal dose (m M A L A T 1 / m H P R T 1 ) of 1 1 1 2 5 7 0 2 5 0 5 0 5 0 5 0 injection P B S to ( — stereopure Control ) improved mouse 5 0 m g eye on oligo in SR 5 0 m g 1 day is 1 . more 5 m g month vivo potent Stereopure 5 0 m g than % m R N A R e m a in in g potency, (m M A L A T 1 / m H P R T 1 ) 1 1 1 2 5 7 0 2 5 0 5 0 5 0 5 0 P B S ( — Control ) 5 0 m g oligo stereorandom 2 extended SR 5 0 m g months 5 m g Stereopure 5 0 m g duration Eye 39
% m R N A R e m a in in g ( m M A L A T 1 / m H P R T 1 ) 1 1 1 2 5 7 0 2 5 0 5 0 5 0 5 0 Front P B S of Control (-) 5 0 m g the Stereopure Experimental SR 5 0 m g 1 eye 10X 5 m g week Single description: lower Stereopure 5 0 m g ASOs: % m R N A R e m a in in g ( m M A L A T 1 / m H P R T 1 ) intravitreal of dose 1 1 1 2 5 7 0 2 5 0 5 0 5 0 5 0 injection P B S to stereopure improved eye mouse Control (-) 5 0 m g in on oligo SR 5 0 m g 1 day is 1. more 5 m g month vivo potent Stereopure 5 0 m g than % m R N A R e m a in in g potency, ( m M A L A T 1 / m H P R T 1 ) 1 1 1 2 5 7 0 2 5 0 5 0 5 0 5 0 P B S Control (-) 5 0 m g oligo stereorandom 2 extended SR 5 0 m g months 5 m g Stereopure 5 0 m g duration Eye 40
Distribution and target engagement Ophthalmology Dermatology Distribution of oligonucleotide to key cellular Target engagement following topical Compartments following intravitreal injection administration on human skin explant model in murine eye Red dots = Oligonucleotides 509452-001 05Jan2018 09:35 QTA Page BS 44 Control Optimized oligonucleotide oligonucleotide 41
Enabling technologies: enhancing stereopure platform Collaboration leverages ReadCoor’s proprietary FISSEQ (Florescent In-Situ Sequencing) platform designed to provide critical spatial data by combining next generation sequencing and three-dimensional imaging Developing a registry of brain cell network maps Advancing chemistry for targeted delivery to the brain 42
Scalable nucleic acid synthesis Oligonucleotide synthesis capacity ranging from high throughput to large scale GMP production 90,000 square foot facility Ability to continue to meet synthesis demands of growing portfolio and increase control and visibility of product supply chain Comparable yield and cost-of-goods to standard stereorandom oligonucleotides Industry standard equipment with no biological processing required GMP manufacturing capacity potentially available to partners 43
Secure patent and intellectual property position Programs HTT candidates DMD candidates ALS, FTD candidates Platform Designs Compositions Stereochemistry Improved activity, Oligonucleotide Monomers, Me stability, specificity, compositions key reagents of s immunogenicity 44
Wave catalysts Q3 2018: data expected in DMD from Phase 1 trial for WVE-210201 – Initiated clinical trial in DMD (Exon 51) November 2017 – WVE-210201 is the first stereopure oligonucleotide targeting Exon 51 with potential to be best-in-class – Interim dystrophin readout from planned efficacy and open label extension trials expected in 2H 2019 Q4 2018: clinical trials expected to initiate in ALS and FTD for WVE-3972-01 – WVE-3972-01 is designed to target the pathogenic allele of the C9orf72 gene – In vivo animal data demonstrate potent, sustained and preferential knockdown of toxic biomarkers associated with ALS and FTD 1H 2019: data expected in HD from Phase 1b/2a trials for WVE-120101 and WVE-120102 – Initiated two clinical trials in HD July 2017 – Potential to be first two allele-specific disease-modifying therapies selectively lowering mHTT – Received U.S. orphan drug designation for WVE-120101 and WVE-120102 Q1 2019: clinical trial expected to initiate for next DMD program (Exon 53) 45
Realizing the potential of nucleic acid therapeutics 46